专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

111. 发明授权

US08193153B2 Trophic factor for the treatment of retinal degenerative diseases 有权
标题翻译：用于治疗视网膜退行性疾病的营养因子
公开(公告)号：US08193153B2
公开(公告)日：2012-06-05
申请号：US12745920
申请日：2008-12-05
申请人： Thierry Leveillard , Jose-Alain Sahel , Valerie Fontaine
发明人： Thierry Leveillard , Jose-Alain Sahel , Valerie Fontaine
IPC分类号： A61K38/16 , A61K38/17 , A61K38/18 , C07K14/435
CPC分类号： C07K16/18 , A61K38/00 , C07K14/47
摘要： This invention relates to methods and compositions for detection and treatment of retinal degenerative diseases. In particular, the invention relates to polypeptides that can protect against cone degeneration, nucleic acid molecules that encode such polypeptides, and antibodies that recognize said polypeptides.
摘要翻译：本发明涉及视网膜退行性疾病的检测和治疗方法和组合物。特别地，本发明涉及可以防止锥形变性的多肽，编码这种多肽的核酸分子和识别所述多肽的抗体。

112. 发明申请

US20120064094A1 Serotonin 5-HT3 Receptor Antagonists for Use in the Treatment of Lesional Vestibular Disorders 有权
标题翻译：血清素5-HT3受体拮抗剂用于治疗损伤性前庭疾病
公开(公告)号：US20120064094A1
公开(公告)日：2012-03-15
申请号：US13321493
申请日：2010-05-20
申请人： Christian Chabbert , Frederic Venail
发明人： Christian Chabbert , Frederic Venail
IPC分类号： A61K39/395 , A61P31/12 , A61P27/16 , A61P25/00 , A61P31/00 , A61K31/7088 , A61K31/4178
CPC分类号： A61K31/4178 , A61K31/4184 , A61K31/437 , A61K31/439 , A61K31/46 , A61K31/4747 , A61K31/496 , A61K31/538 , A61K31/7088
摘要： The invention relates to serotonin 5-HT3 receptor antagonists or inhibitors of serotonin 5-HT3 receptor gene expression for use in the treatment of a lesional vestibular disorder.
摘要翻译：本发明涉及5-羟色胺5-HT 3受体拮抗剂或5-羟色胺5-HT 3受体基因表达抑制剂，用于治疗损伤性前庭疾病。

113. 发明授权

US08124380B2 Glycoconjugates and their use as potential vaccines against infection by Shigella flexneri 有权
标题翻译：糖缀合物及其作为抵抗志贺氏菌感染的潜在疫苗的用途
公开(公告)号：US08124380B2
公开(公告)日：2012-02-28
申请号：US10563221
申请日：2004-07-02
申请人： Armelle Phalipon , Farida Nato , Laurence Mulard , Philippe Sansonetti , Françoise Baleux , Frédéric Belot , Cyrille Grandjean
发明人： Armelle Phalipon , Farida Nato , Laurence Mulard , Philippe Sansonetti , Françoise Baleux , Frédéric Belot , Cyrille Grandjean
IPC分类号： C12P19/00 , C12P19/12 , C07K1/00
CPC分类号： A61K39/0283 , A61K47/557 , A61K47/61 , A61K47/6415 , A61K47/646 , A61K2039/6031 , A61K2039/6037 , A61K2039/625 , C07H3/06 , C07K16/1228 , C07K2317/565 , C08B37/006 , G01N33/563 , G01N33/56916 , Y02A50/476
摘要： A conjugate molecule comprising an oligo- or polysaccharide covalently bound to a carrier and its use as potential vaccine against infection by S. Flexneri.
摘要翻译：共轭分子包含与载体共价结合的寡糖或多糖，并且其用作针对S.Flexneri感染的潜在疫苗。

114. 发明申请

US20110212098A1 Novel Melanoma Antigen Peptide and Uses Thereof 有权
标题翻译：新型黑素瘤抗原肽及其用途
公开(公告)号：US20110212098A1
公开(公告)日：2011-09-01
申请号：US13060484
申请日：2009-09-02
申请人： Nathalie Labarriere , Agnes Moreau-Aubry , Yann Godet
发明人： Nathalie Labarriere , Agnes Moreau-Aubry , Yann Godet
IPC分类号： A61K39/395 , C12N15/63 , C12N5/10 , C12N1/00 , C12N5/0783 , G01N33/574 , C12Q1/68 , C12Q1/02 , C07K7/06 , C07K19/00 , C07K14/00 , C07K16/44 , C07H21/00 , A61K35/12 , A61K31/7088 , A61K48/00 , A61K39/00 , A61P35/00
CPC分类号： C07K7/06 , A61K39/0011 , C07K14/4748 , G01N33/5743
摘要： The present invention relates to novel melanoma antigen peptides and specific T lymphocytes directed to said peptides and the use thereof for treating melanoma.
摘要翻译：本发明涉及针对所述肽的新型黑素瘤抗原肽和特异性T淋巴细胞及其用于治疗黑素瘤的用途。

115. 发明授权

US07985549B2 Method for predicting responsiveness to TNFα blocking agents 有权
标题翻译：预测TNFα阻断剂反应性的方法
公开(公告)号：US07985549B2
公开(公告)日：2011-07-26
申请号：US12300847
申请日：2007-05-15
申请人： Jean-Philippe Salier , Maryvonne Daveau , Anne-Christine Gauthier-Jauneau , Olivier Vittecoq , Xavier Le Loet , Alain Daragon , Othmane Mejjad , Thierry Lequerre
发明人： Jean-Philippe Salier , Maryvonne Daveau , Anne-Christine Gauthier-Jauneau , Olivier Vittecoq , Xavier Le Loet , Alain Daragon , Othmane Mejjad , Thierry Lequerre
IPC分类号： C12Q1/68 , G01N33/53 , C12N15/11 , C12N15/12 , C07H21/04
CPC分类号： C12Q1/6883 , C12Q2600/106
摘要： The invention provides an in vitro method for predicting whether a patient would be responsive to a treatment with a TNFα blocking agent, which method comprises determining the expression level of eight genes in a biological sample of said patient, wherein said genes are EPS15, HLA-DPB1, AKAP9, RASGRP3, MTCBP-1, PTNP12, MRPL22 and RPS28. The invention further provides a DNA chip for performing such method.
摘要翻译：本发明提供一种体外方法，用于预测患者是否对TNFα阻断剂的治疗有反应，该方法包括确定所述患者生物样品中八种基因的表达水平，其中所述基因是EPS15，HLA- DPB1，AKAP9，RASGRP3，MTCBP-1，PTNP12，MRPL22和RPS28。本发明还提供了用于进行这种方法的DNA芯片。

116. 发明申请

US20110065609A1 Methods and Kits for the Diagnosis of Rheumatoid Arthritis 有权
标题翻译：类风湿关节炎诊断方法和试剂盒
公开(公告)号：US20110065609A1
公开(公告)日：2011-03-17
申请号：US12989806
申请日：2009-05-12
申请人： Jean Roudier , Isabelle Auger
发明人： Jean Roudier , Isabelle Auger
IPC分类号： C40B40/10 , G01N33/566
CPC分类号： G01N33/6893 , G01N33/564
摘要： The present invention relates to the identification and use of proteins with clinical relevance to rheumatoid arthritis (RA). In particular, the invention provides the identity of marker proteins that specifically react with RA-associated autoantibodies. Also provided are methods, arrays and kits for using these proteins in the diagnosis of RA, and in the selection and/or monitoring of treatment regimens.
摘要翻译：本发明涉及与类风湿性关节炎（RA）临床相关的蛋白质的鉴定和使用。特别地，本发明提供与RA相关的自身抗体特异性反应的标记蛋白的身份。还提供了在诊断RA中以及在治疗方案的选择和/或监测中使用这些蛋白质的方法，阵列和试剂盒。

117. 发明申请

US20100284991A1 Methods for the Treatment and Diagnosis of Bone Mineral Density Related Diseases 审中-公开
标题翻译：骨矿物质密度相关疾病的治疗和诊断方法
公开(公告)号：US20100284991A1
公开(公告)日：2010-11-11
申请号：US12746456
申请日：2008-12-05
申请人： Valerie Cormier-Daire , Arnold Munnich
发明人： Valerie Cormier-Daire , Arnold Munnich
IPC分类号： A61K38/53 , C12Q1/68 , A61K31/7052 , A61K31/35 , A61P19/08
CPC分类号： C12Q1/6883 , A61K31/357 , A61K38/52 , C12Q2600/136 , C12Q2600/156 , C12Y503/99005
摘要： The present invention relates to methods of the treatment and diagnosis of bone mineral density related disorders. More particularly, the present invention relates to a method of diagnosing or predicting a bone mineral density related disease, or a risk of a bone mineral density related disease, in a subject, which method comprises detecting a mutation in the TBXAS1 gene, wherein the presence of said mutation is indicative of a bone mineral density related disease or of a risk of a bone mineral density related disease. The invention also relates to a compound selected in the group consisting of a thromboxane synthase (TXAS) encoding polynucleotide, a TXAS, thromboxane A2 or an analog thereof for treating or preventing a disease associated with an increased bone mineral density (e.g., Ghosal hematodiaphyseal dysplasia syndrome). The invention also relates to a compound selected from the group consisting of an inhibitor of TBXAS1 gene expression or a thromboxane inhibitor for treating or preventing a disease associated with a decreased bone mineral density (e.g., osteoporosis).
摘要翻译：本发明涉及骨矿物质密度相关疾病的治疗和诊断方法。更具体地，本发明涉及诊断或预测受试者中与骨矿物质密度有关的疾病或骨矿物质密度相关疾病的风险的方法，该方法包括检测TBXAS1基因中的突变，其中存在的所述突变指示与骨矿物质密度相关的疾病或与骨矿物质密度相关的疾病的风险。本发明还涉及一种选自下列的化合物：由血栓烷合成酶（TXAS）编码多核苷酸，TXAS，血栓素A2或其类似物组成的组，用于治疗或预防与骨矿物质密度增加相关的疾病（例如，高原性血管造影发生不良综合征）。本发明还涉及选自TBXAS1基因表达抑制剂或用于治疗或预防与骨矿物质密度降低相关的疾病（例如骨质疏松症）的血栓烷抑制剂的化合物。

118. 发明申请

US20100196921A1 Method for Predicting the Outcome of a Critically Ill Patient 失效
标题翻译：预测重症患者结局的方法
公开(公告)号：US20100196921A1
公开(公告)日：2010-08-05
申请号：US12602118
申请日：2008-05-29
申请人： Francis Schneider , Marie-Helene Metz
发明人： Francis Schneider , Marie-Helene Metz
IPC分类号： G01N33/53 , G01N33/566
CPC分类号： G01N33/78 , G01N2800/26 , G01N2800/56
摘要： The present invention relates to a method for predicting the outcome of a critically ill patient, said method comprising measuring the concentration of Chromogranin A or a fragment thereof in a biological sample obtained from said patient.
摘要翻译：本发明涉及一种用于预测危重患者结局的方法，所述方法包括测量从所述患者获得的生物样品中嗜铬粒蛋白A或其片段的浓度。

119. 发明授权

US07700553B2 Selective inhibition of NF-κB activation by peptides designed to disrupt nemo oligomerization 有权
标题翻译：通过设计用于破坏尼莫低聚的肽对NF-κB活化的选择性抑制
公开(公告)号：US07700553B2
公开(公告)日：2010-04-20
申请号：US10573161
申请日：2004-09-24
申请人： Fabrice Agou , Gilles Courtois , Alain Israel , Michel Veron , Francois Traincard , Shoji Yamaoka , Yves-Marie Coic , Francoise Baleux
发明人： Fabrice Agou , Gilles Courtois , Alain Israel , Michel Veron , Francois Traincard , Shoji Yamaoka , Yves-Marie Coic , Francoise Baleux
IPC分类号： C07K1/00 , A61K38/00
CPC分类号： C07K14/4702 , A61K38/00 , C07K2319/01
摘要： The present invention relates to polypeptides that inhibit the NF-&kgr;B signaling pathway and polynucleotides encoding the same. The present invention further provides methods for the modulation of and/or treatment of inflammatory responses, oncogenesis, viral infection; the regulation of cell proliferation and apoptosis; and regulation of B or T lymphocytes in antigenic stimulation, by administering the polypeptides of the present invention to a subject in need thereof. Finally, the present invention provides a method of identifying polypeptides that modulate oligomerization of NEMO.
摘要翻译：本发明涉及抑制NF-κB信号通路的多肽和编码其的多核苷酸。本发明还提供了调节和/或治疗炎性反应，肿瘤发生，病毒感染的方法; 调节细胞增殖和凋亡; 以及通过将本发明的多肽施用于有需要的受试者来调节抗原刺激中的B或T淋巴细胞。最后，本发明提供了鉴定调节NEMO低聚化的多肽的方法。

120. 发明申请

US20100015653A1 Compounds Regulating Calreticulin, KDEL Receptor and/or ERP-57 Cell Surface Exposure and Uses Thereof to Evaluate the Efficiency of a Cancer Treatment 失效
标题翻译：调节钙网蛋白，KDEL受体和/或ERP-57细胞表面暴露的化合物及其用途来评估癌症治疗的效率
公开(公告)号：US20100015653A1
公开(公告)日：2010-01-21
申请号：US12438975
申请日：2007-09-07
申请人： Guido Kroemer , Laurence Zitvogel , Theocharis Panaretakis
发明人： Guido Kroemer , Laurence Zitvogel , Theocharis Panaretakis
IPC分类号： C12Q1/37 , C12Q1/02
CPC分类号： G01N33/57492 , G01N2500/10 , G01N2800/52
摘要： The present invention relates to a method for determining the susceptibility of a patient tumour cell to a cancer treatment, which method comprises the detection or measure of CRT, KDEL receptor and/or ERp57 on the surface of a tumour cell.
摘要翻译：本发明涉及一种用于确定患者肿瘤细胞对癌症治疗的易感性的方法，该方法包括检测或测量肿瘤细胞表面上的CRT，KDEL受体和/或ERp57。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式